id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-1286-0006,FDA,FDA-2024-E-1286,Determination of Regulatory Review Period for Purposes of Patent Extension; ADZYNMA,Notice,Determinations,2025-12-29T05:00:00Z,2025,12,2025-12-29T05:00:00Z,2026-02-28T04:59:59Z,2025-12-29T19:35:54Z,2025-23864,0,0,09000064b910aaac
FDA-2024-E-1286-0005,FDA,FDA-2024-E-1286,Letter to Troutman Pepper Hamilton Sanders LLP,Other,Letter(s),2025-08-27T04:00:00Z,2025,8,2025-08-27T04:00:00Z,,2025-08-27T22:13:25Z,,0,0,09000064b8f19e40
FDA-2024-E-1286-0004,FDA,FDA-2024-E-1286,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-08-19T04:00:00Z,2025,8,2025-08-19T04:00:00Z,,2025-08-19T21:05:37Z,,0,0,09000064b8f074c7
FDA-2024-E-1286-0003,FDA,FDA-2024-E-1286,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2025-07-02T04:00:00Z,2025,7,2025-07-02T04:00:00Z,,2025-07-02T18:56:51Z,,0,0,09000064b8e434da
FDA-2024-E-1286-0002,FDA,FDA-2024-E-1286,"Patent Term Extension Application for ADZYNMA Patent No 9,351,935",Other,Application,2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T15:55:59Z,,0,0,090000648647da0d
FDA-2024-E-1286-0001,FDA,FDA-2024-E-1286,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T15:55:55Z,,0,0,090000648647d9d5